CA3165738A1 - Treatment of mild traumatic brain injury - Google Patents
Treatment of mild traumatic brain injuryInfo
- Publication number
- CA3165738A1 CA3165738A1 CA3165738A CA3165738A CA3165738A1 CA 3165738 A1 CA3165738 A1 CA 3165738A1 CA 3165738 A CA3165738 A CA 3165738A CA 3165738 A CA3165738 A CA 3165738A CA 3165738 A1 CA3165738 A1 CA 3165738A1
- Authority
- CA
- Canada
- Prior art keywords
- ghrelin
- variant
- days
- mtbi
- symptoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compounds Of Unknown Constitution (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962953130P | 2019-12-23 | 2019-12-23 | |
| US62/953,130 | 2019-12-23 | ||
| PCT/US2020/066703 WO2021133844A1 (en) | 2019-12-23 | 2020-12-22 | Treatment of mild traumatic brain injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3165738A1 true CA3165738A1 (en) | 2021-07-01 |
Family
ID=76575665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3165738A Pending CA3165738A1 (en) | 2019-12-23 | 2020-12-22 | Treatment of mild traumatic brain injury |
Country Status (11)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220370804A1 (en) * | 2021-01-22 | 2022-11-24 | The Regents Of The University Of Colorado, A Body Corporate | Motor learning and vagus nerve stimulation (vns) paired with motor learning to treat demyelinating diseases, conditions and disorders |
| CN113723530B (zh) * | 2021-09-02 | 2022-03-25 | 中国科学院自动化研究所 | 基于视频分析和电子心理沙盘的智能心理评估系统 |
| US20260077018A1 (en) * | 2022-09-07 | 2026-03-19 | Oxeia Biopharmaceuticals, Inc. | Treatment of mild traumatic brain injury |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6545697B2 (ja) * | 2013-11-15 | 2019-07-17 | ニューラル・アナリティクス・インコーポレーテッド | 神経学的状態の診断のための脳の血流速度の構造的特徴をモニタリングすること |
| US9119832B2 (en) * | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
| HK1231413A1 (zh) * | 2014-04-29 | 2017-12-22 | Teva Pharmaceutical Industries Ltd. | 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德 |
| CA2961889A1 (en) * | 2014-08-19 | 2016-02-25 | Oxeia Biopharmaceuticals, Inc. | Methods of treating mild brain injury |
| US20180028617A1 (en) * | 2015-02-19 | 2018-02-01 | The Regents Of The University Of California | Methods of treating mild brain injury and post-traumatic stress disorder |
| WO2016144978A1 (en) * | 2015-03-09 | 2016-09-15 | Oxeia Biopharmaceuticals, Inc. | Methods of treating cognitive impairments or dysfunction |
| WO2017075535A1 (en) * | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
-
2020
- 2020-12-22 AU AU2020412765A patent/AU2020412765A1/en active Pending
- 2020-12-22 CN CN202080092650.7A patent/CN114980915A/zh active Pending
- 2020-12-22 US US17/787,848 patent/US20230031262A1/en active Pending
- 2020-12-22 CA CA3165738A patent/CA3165738A1/en active Pending
- 2020-12-22 WO PCT/US2020/066703 patent/WO2021133844A1/en not_active Ceased
- 2020-12-22 MX MX2022007844A patent/MX2022007844A/es unknown
- 2020-12-22 IL IL294156A patent/IL294156A/en unknown
- 2020-12-22 JP JP2022564096A patent/JP2023508250A/ja active Pending
- 2020-12-22 BR BR112022012365A patent/BR112022012365A2/pt not_active Application Discontinuation
- 2020-12-22 EP EP20905518.5A patent/EP4081238A4/en active Pending
- 2020-12-22 KR KR1020227025653A patent/KR20220122691A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022007844A (es) | 2022-09-07 |
| US20230031262A1 (en) | 2023-02-02 |
| CN114980915A (zh) | 2022-08-30 |
| BR112022012365A2 (pt) | 2022-08-30 |
| JP2023508250A (ja) | 2023-03-01 |
| IL294156A (en) | 2022-08-01 |
| KR20220122691A (ko) | 2022-09-02 |
| AU2020412765A1 (en) | 2022-07-14 |
| WO2021133844A1 (en) | 2021-07-01 |
| EP4081238A1 (en) | 2022-11-02 |
| EP4081238A4 (en) | 2023-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Reich et al. | Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial | |
| Obermann et al. | Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial | |
| Lotery et al. | Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial | |
| Friedman et al. | Diazepam is no better than placebo when added to naproxen for acute low back pain | |
| Decramer et al. | Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials | |
| Steiner et al. | Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study | |
| McGuinness et al. | Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia | |
| Feil et al. | Safety and efficacy of acetyl-DL-leucine in certain types of cerebellar ataxia: the ALCAT randomized clinical crossover trial | |
| EP4081238A1 (en) | Treatment of mild traumatic brain injury | |
| Dart et al. | The Efficacy of Antivenin Latrodectus (Black Widow) Equine Immune F (abʹ) 2 Versus Placebo in the Treatment of Latrodectism: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial | |
| Rose et al. | Treatment for inclusion body myositis | |
| Pearlman et al. | Efficacy and safety of budesonide/formoterol pMDI vs budesonide pMDI in asthmatic children (6–< 12 years) | |
| Papapetropoulos et al. | A phase 2, randomized, double-blind, placebo-controlled trial of CX-8998, a selective modulator of the T-type calcium channel in inadequately treated moderate to severe essential tremor: T-CALM study design and methodology for efficacy endpoint and digital biomarker selection | |
| Smith et al. | Safety and efficacy of topiramate in individuals with cryptogenic sensory peripheral neuropathy with metabolic syndrome: the TopCSPN randomized clinical trial | |
| Attallah et al. | Efficacy, safety and quality of life of oxybutynin versus aluminum chloride hexahydrate in treating primary palmar hyperhidrosis | |
| US20260077018A1 (en) | Treatment of mild traumatic brain injury | |
| Wolstein et al. | A randomized, open-label trial comparing methadone and levo-alpha-acetylmethadol (LAAM) in maintenance treatment of opioid addiction | |
| Stempel et al. | Comparative efficacy and cost of asthma care in children with asthma treated with fluticasone propionate and montelukast | |
| HK40080092A (en) | Treatment of mild traumatic brain injury | |
| Pérez-Garrigues et al. | Patient baseline characteristics in an open-label multinational study of betahistine in recurrent peripheral vestibular vertigo: the OSVaLD study | |
| Khokhar et al. | Vaccination counseling with and without excipient skin testing in patients with suspected allergic reactions to mRNA COVID-19 vaccines and patients with atopy | |
| Hale et al. | Evaluation of Quality of Life, Functioning, Disability, and Work/School Productivity Following Treatment with an Extended‐Release Hydrocodone Tablet Formulated with Abuse‐Deterrence Technology: A 12‐month Open‐label Study in Patients with Chronic Pain | |
| JP2026506974A (ja) | シャルコー・マリー・トゥース病を処置するための組成物及び方法 | |
| Kibleur et al. | French Nationwide Cohort Temporary Utilization Authorization Survey of GranuPAS® in MDR-TB Patients | |
| Davis et al. | Effect of daily dosing with tiotropium against methacholine induced bronchoconstriction in asthmatics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20241205 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241205 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241223 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250424 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260224 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260224 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260226 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260610 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260804 |